Skin care interventions in infants for preventing eczema and food allergy.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
14 11 2022
Historique:
entrez: 14 11 2022
pubmed: 15 11 2022
medline: 16 11 2022
Statut: epublish

Résumé

Eczema and food allergy are common health conditions that usually begin in early childhood and often occur in the same people. They can be associated with an impaired skin barrier in early infancy. It is unclear whether trying to prevent or reverse an impaired skin barrier soon after birth is effective for preventing eczema or food allergy. Primary objective To assess the effects of skin care interventions such as emollients for primary prevention of eczema and food allergy in infants. Secondary objective To identify features of study populations such as age, hereditary risk, and adherence to interventions that are associated with the greatest treatment benefit or harm for both eczema and food allergy. We performed an updated search of the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, and Embase in September 2021. We searched two trials registers in July 2021. We checked the reference lists of included studies and relevant systematic reviews, and scanned conference proceedings to identify further references to relevant randomised controlled trials (RCTs).  SELECTION CRITERIA: We included RCTs of skin care interventions that could potentially enhance skin barrier function, reduce dryness, or reduce subclinical inflammation in healthy term (> 37 weeks) infants (≤ 12 months) without pre-existing eczema, food allergy, or other skin condition. Eligible comparisons were standard care in the locality or no treatment. Types of skin care interventions could include moisturisers/emollients; bathing products; advice regarding reducing soap exposure and bathing frequency; and use of water softeners. No minimum follow-up was required. This is a prospective individual participant data (IPD) meta-analysis. We used standard Cochrane methodological procedures, and primary analyses used the IPD dataset. Primary outcomes were cumulative incidence of eczema and cumulative incidence of immunoglobulin (Ig)E-mediated food allergy by one to three years, both measured at the closest available time point to two years. Secondary outcomes included adverse events during the intervention period; eczema severity (clinician-assessed); parent report of eczema severity; time to onset of eczema; parent report of immediate food allergy; and allergic sensitisation to food or inhalant allergen. We identified 33 RCTs comprising 25,827 participants. Of these, 17 studies randomising 5823 participants reported information on one or more outcomes specified in this review.  We included 11 studies, randomising 5217 participants, in one or more meta-analyses (range 2 to 9 studies per individual meta-analysis), with 10 of these studies providing IPD; the remaining 6 studies were included in the narrative results only.   Most studies were conducted at children's hospitals. Twenty-five studies, including all those contributing data to meta-analyses, randomised newborns up to age three weeks to receive a skin care intervention or standard infant skin care. Eight of the 11 studies contributing to meta-analyses recruited infants at high risk of developing eczema or food allergy, although the definition of high risk varied between studies. Durations of intervention and follow-up ranged from 24 hours to three years. All interventions were compared against no skin care intervention or local standard care. Of the 17 studies that reported information on our prespecified outcomes, 13 assessed emollients. We assessed most of the evidence in the review as low certainty and had some concerns about risk of bias. A rating of some concerns was most often due to lack of blinding of outcome assessors or significant missing data, which could have impacted outcome measurement but was judged unlikely to have done so. We assessed the evidence for the primary food allergy outcome as high risk of bias due to the inclusion of only one trial, where findings varied based on different assumptions about missing data. Skin care interventions during infancy probably do not change the risk of eczema by one to three years of age (risk ratio (RR) 1.03, 95% confidence interval (CI) 0.81 to 1.31; risk difference 5 more cases per 1000 infants, 95% CI 28 less to 47 more; moderate-certainty evidence; 3075 participants, 7 trials) or time to onset of eczema (hazard ratio 0.86, 95% CI 0.65 to 1.14; moderate-certainty evidence; 3349 participants, 9 trials). Skin care interventions during infancy may increase the risk of IgE-mediated food allergy by one to three years of age (RR 2.53, 95% CI 0.99 to 6.49; low-certainty evidence; 976 participants, 1 trial) but may not change risk of allergic sensitisation to a food allergen by age one to three years (RR 1.05, 95% CI 0.64 to 1.71; low-certainty evidence; 1794 participants, 3 trials). Skin care interventions during infancy may slightly increase risk of parent report of immediate reaction to a common food allergen at two years (RR 1.27, 95% CI 1.00 to 1.61; low-certainty evidence; 1171 participants, 1 trial); however, this was only seen for cow's milk, and may be unreliable due to over-reporting of milk allergy in infants. Skin care interventions during infancy probably increase risk of skin infection over the intervention period (RR 1.33, 95% CI 1.01 to 1.75; risk difference 17 more cases per 1000 infants, 95% CI one more to 38 more; moderate-certainty evidence; 2728 participants, 6 trials) and may increase the risk of infant slippage over the intervention period (RR 1.42, 95% CI 0.67 to 2.99; low-certainty evidence; 2538 participants, 4 trials) and stinging/allergic reactions to moisturisers (RR 2.24, 95% 0.67 to 7.43; low-certainty evidence; 343 participants, 4 trials), although CIs for slippages and stinging/allergic reactions were wide and include the possibility of no effect or reduced risk. Preplanned subgroup analyses showed that the effects of interventions were not influenced by age, duration of intervention, hereditary risk, filaggrin (FLG) mutation, chromosome 11 intergenic variant rs2212434, or classification of intervention type for risk of developing eczema. We could not evaluate these effects on risk of food allergy. Evidence was insufficient to show whether adherence to interventions influenced the relationship between skin care interventions and eczema or food allergy development. Based on low- to moderate-certainty evidence, skin care interventions such as emollients during the first year of life in healthy infants are probably not effective for preventing eczema; may increase risk of food allergy; and probably increase risk of skin infection. Further study is needed to understand whether different approaches to infant skin care might prevent eczema or food allergy.

Sections du résumé

BACKGROUND
Eczema and food allergy are common health conditions that usually begin in early childhood and often occur in the same people. They can be associated with an impaired skin barrier in early infancy. It is unclear whether trying to prevent or reverse an impaired skin barrier soon after birth is effective for preventing eczema or food allergy.
OBJECTIVES
Primary objective To assess the effects of skin care interventions such as emollients for primary prevention of eczema and food allergy in infants. Secondary objective To identify features of study populations such as age, hereditary risk, and adherence to interventions that are associated with the greatest treatment benefit or harm for both eczema and food allergy.
SEARCH METHODS
We performed an updated search of the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, and Embase in September 2021. We searched two trials registers in July 2021. We checked the reference lists of included studies and relevant systematic reviews, and scanned conference proceedings to identify further references to relevant randomised controlled trials (RCTs).  SELECTION CRITERIA: We included RCTs of skin care interventions that could potentially enhance skin barrier function, reduce dryness, or reduce subclinical inflammation in healthy term (> 37 weeks) infants (≤ 12 months) without pre-existing eczema, food allergy, or other skin condition. Eligible comparisons were standard care in the locality or no treatment. Types of skin care interventions could include moisturisers/emollients; bathing products; advice regarding reducing soap exposure and bathing frequency; and use of water softeners. No minimum follow-up was required.
DATA COLLECTION AND ANALYSIS
This is a prospective individual participant data (IPD) meta-analysis. We used standard Cochrane methodological procedures, and primary analyses used the IPD dataset. Primary outcomes were cumulative incidence of eczema and cumulative incidence of immunoglobulin (Ig)E-mediated food allergy by one to three years, both measured at the closest available time point to two years. Secondary outcomes included adverse events during the intervention period; eczema severity (clinician-assessed); parent report of eczema severity; time to onset of eczema; parent report of immediate food allergy; and allergic sensitisation to food or inhalant allergen.
MAIN RESULTS
We identified 33 RCTs comprising 25,827 participants. Of these, 17 studies randomising 5823 participants reported information on one or more outcomes specified in this review.  We included 11 studies, randomising 5217 participants, in one or more meta-analyses (range 2 to 9 studies per individual meta-analysis), with 10 of these studies providing IPD; the remaining 6 studies were included in the narrative results only.   Most studies were conducted at children's hospitals. Twenty-five studies, including all those contributing data to meta-analyses, randomised newborns up to age three weeks to receive a skin care intervention or standard infant skin care. Eight of the 11 studies contributing to meta-analyses recruited infants at high risk of developing eczema or food allergy, although the definition of high risk varied between studies. Durations of intervention and follow-up ranged from 24 hours to three years. All interventions were compared against no skin care intervention or local standard care. Of the 17 studies that reported information on our prespecified outcomes, 13 assessed emollients. We assessed most of the evidence in the review as low certainty and had some concerns about risk of bias. A rating of some concerns was most often due to lack of blinding of outcome assessors or significant missing data, which could have impacted outcome measurement but was judged unlikely to have done so. We assessed the evidence for the primary food allergy outcome as high risk of bias due to the inclusion of only one trial, where findings varied based on different assumptions about missing data. Skin care interventions during infancy probably do not change the risk of eczema by one to three years of age (risk ratio (RR) 1.03, 95% confidence interval (CI) 0.81 to 1.31; risk difference 5 more cases per 1000 infants, 95% CI 28 less to 47 more; moderate-certainty evidence; 3075 participants, 7 trials) or time to onset of eczema (hazard ratio 0.86, 95% CI 0.65 to 1.14; moderate-certainty evidence; 3349 participants, 9 trials). Skin care interventions during infancy may increase the risk of IgE-mediated food allergy by one to three years of age (RR 2.53, 95% CI 0.99 to 6.49; low-certainty evidence; 976 participants, 1 trial) but may not change risk of allergic sensitisation to a food allergen by age one to three years (RR 1.05, 95% CI 0.64 to 1.71; low-certainty evidence; 1794 participants, 3 trials). Skin care interventions during infancy may slightly increase risk of parent report of immediate reaction to a common food allergen at two years (RR 1.27, 95% CI 1.00 to 1.61; low-certainty evidence; 1171 participants, 1 trial); however, this was only seen for cow's milk, and may be unreliable due to over-reporting of milk allergy in infants. Skin care interventions during infancy probably increase risk of skin infection over the intervention period (RR 1.33, 95% CI 1.01 to 1.75; risk difference 17 more cases per 1000 infants, 95% CI one more to 38 more; moderate-certainty evidence; 2728 participants, 6 trials) and may increase the risk of infant slippage over the intervention period (RR 1.42, 95% CI 0.67 to 2.99; low-certainty evidence; 2538 participants, 4 trials) and stinging/allergic reactions to moisturisers (RR 2.24, 95% 0.67 to 7.43; low-certainty evidence; 343 participants, 4 trials), although CIs for slippages and stinging/allergic reactions were wide and include the possibility of no effect or reduced risk. Preplanned subgroup analyses showed that the effects of interventions were not influenced by age, duration of intervention, hereditary risk, filaggrin (FLG) mutation, chromosome 11 intergenic variant rs2212434, or classification of intervention type for risk of developing eczema. We could not evaluate these effects on risk of food allergy. Evidence was insufficient to show whether adherence to interventions influenced the relationship between skin care interventions and eczema or food allergy development.
AUTHORS' CONCLUSIONS
Based on low- to moderate-certainty evidence, skin care interventions such as emollients during the first year of life in healthy infants are probably not effective for preventing eczema; may increase risk of food allergy; and probably increase risk of skin infection. Further study is needed to understand whether different approaches to infant skin care might prevent eczema or food allergy.

Identifiants

pubmed: 36373988
doi: 10.1002/14651858.CD013534.pub3
pmc: PMC9661877
doi:

Substances chimiques

Emollients 0
Allergens 0

Types de publication

Meta-Analysis Journal Article Review Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD013534

Commentaires et corrections

Type : UpdateOf

Informations de copyright

Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

Références

J Pediatr Nurs. 2018 Sep - Oct;42:e52-e57
pubmed: 29779763
Minerva Pediatr. 2005 Dec;57(6):411-8
pubmed: 16402012
Indian Pediatr. 2005 Sep;42(9):877-84
pubmed: 16208048
J Matern Fetal Neonatal Med. 2005 Jan;17(1):59-62
pubmed: 15804789
J Invest Dermatol. 2008 Jul;128(7):1728-36
pubmed: 18200056
Lancet. 2020 Mar 21;395(10228):962-972
pubmed: 32087126
Pediatr Dermatol. 2020 Jan;37(1):115-119
pubmed: 31691352
Eur J Pediatr. 2019 Sep;178(9):1317-1324
pubmed: 31267223
Br J Dermatol. 2020 Aug;183(2):285-293
pubmed: 31599965
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Clin Dermatol. 1996 Jan-Feb;14(1):81-4
pubmed: 8901403
Nat Genet. 2013 Aug;45(8):902-906
pubmed: 23817571
Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004262
pubmed: 16856040
JAMA. 2016 Sep 20;316(11):1181-1192
pubmed: 27654604
Biomed Res Int. 2018 Jul 12;2018:1302465
pubmed: 30112358
J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):440-448.e2
pubmed: 29248387
Pediatr Dermatol. 2011 Sep-Oct;28(5):593-5
pubmed: 21895755
J Drugs Dermatol. 2018 May 1;17(5):566-570
pubmed: 29742190
Skin Pharmacol Physiol. 2016;29(3):148-56
pubmed: 27271265
J Allergy Clin Immunol. 2003 Dec;112(6):1203-7
pubmed: 14657884
JAMA Pediatr. 2013 Nov;167(11):1026-31
pubmed: 24042236
Am J Trop Med Hyg. 2020 Nov;103(5):2116-2126
pubmed: 32959761
Kinderkrankenschwester. 2009 Mar;28(3):116-25
pubmed: 19382435
N Engl J Med. 1964 Feb 20;270:379-86
pubmed: 14087039
Allergy Asthma Clin Immunol. 2019 Nov 26;15:74
pubmed: 31788007
BMJ Open. 2019 Mar 13;9(3):e024594
pubmed: 30867201
Clin Exp Dermatol. 2020 Dec;45(8):974-979
pubmed: 32852805
J Obstet Gynecol Neonatal Nurs. 2001 Jan-Feb;30(1):41-51
pubmed: 11277161
Ann Allergy Asthma Immunol. 2017 Aug;119(2):111-119
pubmed: 28801016
JAMA Netw Open. 2019 Jan 4;2(1):e185630
pubmed: 30646188
Can Med Assoc J. 1977 Aug 6;117(3):223-6
pubmed: 328126
Br J Dermatol. 1998 Nov;139(5):834-9
pubmed: 9892950
J Pediatr Nurs. 2016 Sep-Oct;31(5):e313-22
pubmed: 27136715
Dermatology. 2014;229(3):230-9
pubmed: 25323538
Cochrane Database Syst Rev. 2000;(2):CD001150
pubmed: 10796254
Allergy. 2017 Mar;72(3):453-461
pubmed: 27670637
Pediatr Dermatol. 2012 Jan-Feb;29(1):1-14
pubmed: 22011065
J Allergy Clin Immunol. 2017 May;139(5):1568-1574.e1
pubmed: 28017882
Allergol Immunopathol (Madr). 2014 Nov-Dec;42(6):539-43
pubmed: 25201763
J Clin Epidemiol. 2008 Jan;61(1):64-75
pubmed: 18083463
J Med Assoc Thai. 2016 Nov;99 Suppl 8:S1-S6
pubmed: 29901362
J Allergy Clin Immunol. 2016 Apr;137(4):1071-1078
pubmed: 26897122
J Invest Dermatol. 2018 Jan;138(1):68-77
pubmed: 28927888
J Allergy Clin Immunol. 2018 Mar;141(3):991-1001
pubmed: 29030101
J Clin Invest. 2004 Mar;113(5):651-7
pubmed: 14991059
J Obstet Gynecol Neonatal Nurs. 2004 Nov-Dec;33(6):704-12
pubmed: 15561658
N Engl J Med. 2016 May 5;374(18):1733-43
pubmed: 26943128
BMC Dermatol. 2012 Apr 04;12:3
pubmed: 22471265
J Am Acad Dermatol. 2018 Sep;79(3):448-456.e30
pubmed: 30119868
Stat Med. 2008 Feb 28;27(5):746-63
pubmed: 17592831
Pediatrics. 1993 Sep;92(3):415-9
pubmed: 8361795
J Perinatol. 2010 Jun;30(6):414-9
pubmed: 19890343
J Health Popul Nutr. 2007 Jun;25(2):236-40
pubmed: 17985826
J Tissue Viability. 2017 Feb;26(1):29-36
pubmed: 27090800
Arch Dermatol. 2004 Dec;140(12):1513-9
pubmed: 15611432
Lancet. 2017 Jan 21;389(10066):276-286
pubmed: 27939035
J Allergy Clin Immunol. 2016 Apr;137(4):1111-1116.e8
pubmed: 26924469
Allergy. 2014 Jan;69(1):3-16
pubmed: 24417229
Skin Res Technol. 2017 Nov;23(4):545-551
pubmed: 28303612
J Allergy Clin Immunol Pract. 2020 Mar;8(3):1014-1021
pubmed: 31733336
Clin Exp Allergy. 2020 Mar;50(3):334-342
pubmed: 31999862
Pediatr Dermatol. 2012 May-Jun;29(3):270-6
pubmed: 22260233
J Obstet Gynecol Neonatal Nurs. 2013 Mar-Apr;42(2):203-14
pubmed: 23421327
J Allergy Clin Immunol. 2004 May;113(5):832-6
pubmed: 15131563
J Spec Pediatr Nurs. 2013 Apr;18(2):123-32
pubmed: 23560584
Pediatr Dermatol. 2014 Nov-Dec;31(6):683-91
pubmed: 25424209
J Allergy Clin Immunol. 2021 Mar;147(3):967-976.e1
pubmed: 33678253
Curr Allergy Asthma Rep. 2008 May;8(3):188-94
pubmed: 18589836
Indian Pediatr. 2005 Oct;42(10):998-1005
pubmed: 16269830
J Obstet Gynecol Neonatal Nurs. 2005 Nov-Dec;34(6):741-6
pubmed: 16282232
Ann Allergy Asthma Immunol. 2018 Feb;120(2):145-151
pubmed: 29413338
J Med Assoc Thai. 2001 Jun;84(6):837-41
pubmed: 11556462
J Allergy Clin Immunol. 2010 Dec;126(6 Suppl):S1-58
pubmed: 21134576
J Eur Acad Dermatol Venereol. 2012 Aug;26(8):1045-60
pubmed: 22805051
Clin Dermatol. 2012 May-Jun;30(3):286-96
pubmed: 22507043
Allergy. 2018 Jun;73(6):1284-1293
pubmed: 29319189
Pediatr Allergy Immunol. 2020 Oct;31(7):813-826
pubmed: 32396244
Lancet. 2020 Mar 21;395(10228):951-961
pubmed: 32087121
J Allergy Clin Immunol. 2019 Feb;143(2):662-668.e2
pubmed: 30096388
Appl Nurs Res. 2018 Apr;40:34-38
pubmed: 29579496
BMC Pregnancy Childbirth. 2020 Sep 16;20(1):540
pubmed: 32938433
Allergy. 2011 Feb;66(2):206-13
pubmed: 20804468
Pediatr Res. 2007 May;61(5 Pt 1):588-93
pubmed: 17413870
Indian Pediatr. 1969 Nov;6(11):697-700
pubmed: 5375505
Exp Dermatol. 2001 Feb;10(1):11-8
pubmed: 11168575
J Allergy Clin Immunol. 2019 Dec;144(6):1615-1623
pubmed: 31812185
Niger Med J. 2016 May-Jun;57(3):160-3
pubmed: 27397955
Br J Dermatol. 2012 Mar;166(3):483-90
pubmed: 21967466
Allergol Int. 2018 Jan;67(1):24-31
pubmed: 29233462
Spine (Phila Pa 1976). 2009 Aug 15;34(18):1929-41
pubmed: 19680101
BMJ Open. 2019 Aug 20;9(8):e027168
pubmed: 31434765
Pediatr Dermatol. 2005 May-Jun;22(3):192-9
pubmed: 15916563
J Pediatr. 2015 Mar;166(3):777-8
pubmed: 25722275
Pediatrics. 2000 Jul;106(1 Pt 1):105-8
pubmed: 10878157
Curr Opin Allergy Clin Immunol. 2015 Oct;15(5):426-34
pubmed: 26226353
J Allergy Clin Immunol. 2014 Oct;134(4):824-830.e6
pubmed: 25282564
BMJ. 2009 Jul 09;339:b2433
pubmed: 19589816
Br J Dermatol. 2018 Aug;179(2):431-441
pubmed: 29691836
J Trop Pediatr. 2015 Dec;61(6):414-20
pubmed: 26338490
Exp Dermatol. 2019 Nov;28(11):1289-1297
pubmed: 31472099
Allergol Int. 2016 Jan;65(1):103-8
pubmed: 26666481
J Am Acad Dermatol. 2014 Jul;71(1):177-84
pubmed: 24656726
Stat Med. 2006 Oct 30;25(20):3443-57
pubmed: 16345038
Int J Cosmet Sci. 2011 Feb;33(1):17-24
pubmed: 20807257
Br J Dermatol. 2019 Oct;181(4):707-716
pubmed: 30693473
Indian Pediatr. 2010 Nov;47(11):959-63
pubmed: 20453263
Clin Exp Allergy. 2010 Aug;40(8):1247-55
pubmed: 20545710
World Allergy Organ J. 2014 May 19;7(1):12
pubmed: 24940476
J Allergy Clin Immunol. 2018 Jan;141(1):41-58
pubmed: 29157945
Skin Pharmacol Physiol. 2004 Mar-Apr;17(2):57-66
pubmed: 14976382
J Allergy Clin Immunol. 2011 Mar;127(3):668-76.e1-2
pubmed: 21377036
PLoS One. 2017 Jun 2;12(6):e0178539
pubmed: 28575026
Clin Exp Allergy. 2013 Jun;43(6):642-51
pubmed: 23711126
JAMA Pediatr. 2020 Jun 1;174(6):599-608
pubmed: 32282040
Br J Dermatol. 2011 Aug;165(2):329-34
pubmed: 21564067
Scand J Infect Dis. 2008;40(8):615-20
pubmed: 18979599
J Obstet Gynecol Neonatal Nurs. 2000 Nov-Dec;29(6):584-9
pubmed: 11110328
Eur J Immunol. 2004 Aug;34(8):2100-9
pubmed: 15259007
Am J Infect Control. 2020 Nov;48(11):1315-1321
pubmed: 32303373
Acta Derm Venereol. 2016 Mar;96(3):323-30
pubmed: 26551528
Nord Med. 1971 Dec 2;86(48):1425-9
pubmed: 5133980
Eur Clin Respir J. 2015 Mar 24;2:
pubmed: 26557262
J Allergy Clin Immunol. 2019 Aug;144(2):494-503
pubmed: 31160034
Clin Exp Allergy. 2005 Jun;35(6):757-66
pubmed: 15969667
JAMA. 2010 Feb 17;303(7):623-30
pubmed: 20159870
Australas J Dermatol. 2021 Nov;62(4):e539-e545
pubmed: 34424533
Clin Exp Allergy. 2013 Dec;43(12):1333-41
pubmed: 24118190
Child Care Health Dev. 2009 Jan;35(1):96-105
pubmed: 18991972
Lancet. 2015 Feb 26;385 Suppl 1:S31
pubmed: 26312853
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Curr Ther Res Clin Exp. 1974 May;16(5):452-6
pubmed: 4275656
J Antimicrob Chemother. 1979 Mar;5(2):235-6
pubmed: 107154
N Engl J Med. 2011 Oct 6;365(14):1315-27
pubmed: 21991953
Pediatr Infect Dis J. 2004 Aug;23(8):719-25
pubmed: 15295221
Allergy. 2018 Mar;73(3):696-704
pubmed: 28960336
Midwifery. 2018 Jan;56:29-43
pubmed: 29055852
J Clin Epidemiol. 2018 Apr;96:126-132
pubmed: 29157924
J Invest Dermatol. 2017 Jan;137(1):26-30
pubmed: 27616422
Cochrane Database Syst Rev. 2021 Feb 5;2:CD013534
pubmed: 33545739
Clin Cosmet Investig Dermatol. 2019 Dec 16;12:895-909
pubmed: 31908513
J Perinatol. 2005 Jun;25(6):375-9
pubmed: 15858603
Clin Exp Allergy. 2015 Jan;45(1):255-64
pubmed: 25210971
Clin Exp Allergy. 2004 Apr;34(4):520-6
pubmed: 15080802
Br J Dermatol. 2010 Dec;163(6):1333-6
pubmed: 21137118
N Engl J Med. 2015 Feb 26;372(9):803-13
pubmed: 25705822
J Allergy Clin Immunol. 2012 Jul;130(1):137-44
pubmed: 22424882
Pediatr Dermatol. 2008 Mar-Apr;25(2):174-8
pubmed: 18429773
Exp Dermatol. 2023 Jan;32(1):75-77
pubmed: 36204776
J Trop Pediatr. 2020 Apr 1;66(2):129-135
pubmed: 31257430
J Pediatr Gastroenterol Nutr. 2000 Oct;31(4):387-90
pubmed: 11045835
Expert Rev Clin Immunol. 2019 Feb;15(2):147-152
pubmed: 30412431
Int Arch Allergy Immunol. 2019;180(3):202-211
pubmed: 31394530
Biomed Hub. 2021 Jan 18;6(1):17-34
pubmed: 33791313
Lancet. 2016 Mar 12;387(10023):1109-1122
pubmed: 26377142
BMC Pediatr. 2011 May 13;11:35
pubmed: 21569487
Lancet. 2005 Mar 19-25;365(9464):1039-45
pubmed: 15781099
BMC Pregnancy Childbirth. 2021 Feb 11;21(1):123
pubmed: 33573612
BMC Pediatr. 2012 Jun 01;12:59
pubmed: 22656391
J Dermatol. 2018 Jan;45(1):24-30
pubmed: 28983938
J Allergy Clin Immunol. 2007 Oct;120(4):878-84
pubmed: 17931562
Allergy. 2020 Sep;75(9):2383-2387
pubmed: 32323869
Curr Opin Allergy Clin Immunol. 2016 Jun;16(3):265-71
pubmed: 27057796
J Hosp Infect. 1986 Jan;7(1):91-5
pubmed: 2870116
Cochrane Database Syst Rev. 2017 Feb 06;2:CD012119
pubmed: 28166390
Bull World Health Organ. 2010 Feb;88(2):104-12
pubmed: 20428367
Int J Dermatol. 2017 Nov;56(11):1198-1203
pubmed: 28884798
Skin Pharmacol Physiol. 2009;22(5):248-57
pubmed: 19690450
Br J Dermatol. 2018 Jan;178(1):e19-e21
pubmed: 28639306
Evid Based Child Health. 2011 Sep;6(5):1322-1339
pubmed: 22822349
J Adv Nurs. 2021 Feb;77(2):1051-1061
pubmed: 33210328
Allergy. 2018 Oct;73(10):2063-2070
pubmed: 29710408
Br J Dermatol. 1994 Sep;131(3):383-96
pubmed: 7918015
J Obstet Gynecol Neonatal Nurs. 2001 Jan-Feb;30(1):30-40
pubmed: 11277160
Pediatr Dermatol. 2014 Jul-Aug;31(4):413-29
pubmed: 24890321
J Clin Epidemiol. 2013 Jul;66(7):726-35
pubmed: 23570745
Dermatology. 1997;195(3):258-62
pubmed: 9407174
Arch Dis Child. 1997 Feb;76(2):159-62
pubmed: 9068310
J Med Assoc Thai. 2002 Jan;85(1):102-6
pubmed: 12075708
Birth. 1986 Sep;13(3):176-80
pubmed: 3535823
Neonatal Netw. 2015;34(4):227-30
pubmed: 26802637
J Allergy Clin Immunol Pract. 2014 Sep-Oct;2(5):629-30
pubmed: 25213063
Pediatr Infect Dis J. 2014 Nov;33(11):1124-7
pubmed: 24853544
Curr Opin Pediatr. 2005 Aug;17(4):481-5
pubmed: 16012260
Lancet. 2006 Aug 26;368(9537):733-43
pubmed: 16935684
BMJ. 2010 Feb 05;340:c221
pubmed: 20139215
Eur J Clin Nutr. 2002 Jan;56(1):31-6
pubmed: 11840177
J Trop Pediatr. 2015 Dec;61(6):428-34
pubmed: 26314307
BMC Nutr. 2020 Sep 14;6:46
pubmed: 32944265
Trials. 2020 Mar 4;21(1):243
pubmed: 32131885
Indian Pediatr. 2010 Jul;47(7):593-8
pubmed: 20683112
Arch Kinderheilkd. 1965 May;172(2):154-60
pubmed: 5318410
Pediatrics. 2007 Feb;119(2):e330-40
pubmed: 17210728
BMC Public Health. 2013;13 Suppl 3:S31
pubmed: 24564550
BMC Res Notes. 2020 Sep 14;13(1):430
pubmed: 32928289
Pediatr Dermatol. 2016 May;33(3):311-21
pubmed: 26919683
PLoS One. 2018 Feb 28;13(2):e0192443
pubmed: 29489859
Neonatology. 2009;96(4):226-34
pubmed: 19407468
PLoS One. 2012;7(7):e39803
pubmed: 22808063
Exp Dermatol. 2009 Nov;18(11):954-61
pubmed: 19555376
J Fam Health. 2015 May-Jun;25(3):10, 12
pubmed: 26118287
J Eur Acad Dermatol Venereol. 2019 Nov;33(11):2087-2094
pubmed: 31287580
Allergy. 2010 Aug;65(8):933-45
pubmed: 20180792
J Am Acad Dermatol. 2014 Jul;71(1):116-32
pubmed: 24813302
J Dtsch Dermatol Ges. 2011 Dec;9(12):1018-25
pubmed: 21672163
J Allergy Clin Immunol. 2007 Sep;120(3):565-9
pubmed: 17655920
Allergy. 2008 Mar;63(3):354-9
pubmed: 18053008
Trials. 2017 Jul 21;18(1):343
pubmed: 28732519
J Pediatr. 1996 May;128(5 Pt 1):660-9
pubmed: 8627439
Nat Genet. 2009 May;41(5):596-601
pubmed: 19349984
Int J Nurs Stud. 2017 Jan;65:17-24
pubmed: 27815985
J Allergy Clin Immunol. 2010 Jan;125(1):170-4.e1-2
pubmed: 20109745
J Allergy Clin Immunol. 2014 Oct;134(4):818-23
pubmed: 25282563
J Allergy Clin Immunol. 2003 Dec;112(6 Suppl):S118-27
pubmed: 14657842
J Allergy Clin Immunol. 2014 Dec;134(6):1318-1328.e7
pubmed: 25280385
Pediatr Dermatol. 2010 Mar-Apr;27(2):125-31
pubmed: 19804498
J Allergy Clin Immunol. 2015 Apr;135(4):956-963.e1
pubmed: 25468198
Cochrane Database Syst Rev. 2004;(1):CD001150
pubmed: 14973963
World Allergy Organ J. 2013 Dec 04;6(1):21
pubmed: 24304599
J Eur Acad Dermatol Venereol. 2001 Sep;15 Suppl 1:5-11
pubmed: 11720074
Dermatol Ther. 2004;17 Suppl 1:49-56
pubmed: 14728699
J Matern Fetal Neonatal Med. 2015 Jan;28(1):33-6
pubmed: 24588277
Nat Genet. 2006 Apr;38(4):441-6
pubmed: 16550169
Cochrane Database Syst Rev. 2016 Jan 29;(1):CD001150
pubmed: 26824786
PLoS Med. 2018 Feb 28;15(2):e1002507
pubmed: 29489823
Pediatr Dermatol. 2010 Jan-Feb;27(1):1-8
pubmed: 20199402
Br J Rheumatol. 1995 May;34(5):479-80
pubmed: 7788182
Arch Dis Child Fetal Neonatal Ed. 2015 May;100(3):F210-5
pubmed: 25637007
Curr Opin Pediatr. 2002 Oct;14(5):634-46
pubmed: 12352260
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
J Cosmet Dermatol. 2017 Dec;16(4):500-507
pubmed: 28070970
Pediatrics. 2008 Mar;121(3):522-9
pubmed: 18310201
J Allergy Clin Immunol. 2019 Sep;144(3):710-719
pubmed: 31260715
Early Hum Dev. 2008 Jun;84(6):399-401
pubmed: 18053656

Auteurs

Maeve M Kelleher (MM)

National Heart & Lung Institute, Section of Inflammation and Repair, Imperial College London, London, UK.

Rachel Phillips (R)

Imperial Clinical Trials Unit, Imperial College London, London, UK.

Sara J Brown (SJ)

Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, UK.

Suzie Cro (S)

Imperial Clinical Trials Unit, Imperial College London, London, UK.

Victoria Cornelius (V)

Imperial Clinical Trials Unit, Imperial College London, London, UK.

Karin C Lødrup Carlsen (KCL)

Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Håvard O Skjerven (HO)

Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.

Eva M Rehbinder (EM)

Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Dermatology, Oslo University Hospital, Oslo, Norway.

Adrian J Lowe (AJ)

Allergy and Lung Health Unit, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia.

Eishika Dissanayake (E)

Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Naoki Shimojo (N)

Center for Preventive Medical Sciences, Chiba University, Chiba, Japan.

Kaori Yonezawa (K)

Department of Midwifery and Women's Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Yukihiro Ohya (Y)

Allergy Center, National Center for Child Health and Development, Tokyo, Japan.

Kiwako Yamamoto-Hanada (K)

Allergy Center, National Center for Child Health and Development, Tokyo, Japan.

Kumiko Morita (K)

Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.

Emma Axon (E)

Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.

Michael Cork (M)

Sheffield Dermatology Research, Department of Infection, Immunity & Cardiovascular Disease, The University of Sheffield, Sheffield, UK.

Alison Cooke (A)

Division of Nursing, Midwifery and Social Work, School of Health Sciences, The University of Manchester, Manchester, UK.

Eleanor Van Vogt (E)

Imperial Clinical Trials Unit, Imperial College London, London, UK.

Jochen Schmitt (J)

Center for Evidence-Based Healthcare, Faculty of Medicine Carl Gustav Carus, Technischen Universität (TU) Dresden, Dresden, Germany.

Stephan Weidinger (S)

Department of Dermatology and Allergy, University Hospital Scheswig-Holstein, Kiel, Germany.

Danielle McClanahan (D)

Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA.

Eric Simpson (E)

Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA.

Lelia Duley (L)

Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.

Lisa M Askie (LM)

NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.

Hywel C Williams (HC)

Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.

Robert J Boyle (RJ)

National Heart & Lung Institute, Section of Inflammation and Repair, Imperial College London, London, UK.
Cochrane Skin, Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH